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Abstract 
Drug benefit-risk analysis is based on firm clinical evidence related to various safety 
and efficacy outcomes, such as tolerability, treatment response, and adverse events. In 
this paper, we propose a new approach for constructing a supporting multi-criteria 
model that fully takes into account this evidence. Our approach is based on the 
Stochastic Multicriteria Acceptability Analysis (SMAA) methodology, which allows 
us to compute the typical value judgments that support a decision, to quantify 
uncertainty, and to compute a comprehensive benefit-risk profile. As an example, we 
constructed a multi-criteria model for the therapeutic group of second-generation 
antidepressants. We analyzed Fluoxetine, Paroxetine, Sertraline, and Venlafaxine 
according to relative efficacy and absolute rates of several common adverse drug 
reactions using meta-analytical data from the literature. Our model showed that there 
are clear trade-offs among the four drugs. Based on our experiences from this study, 
SMAA appears to be a suitable approach for quantifying trade-offs and decision 
uncertainty in drug benefit-risk analysis. 
Keywords: clinical pharmacology; decision analysis; simulation methods; meta-
analysis; risk communication  3 
 
1  Introduction 
Drug Benefit-Risk (BR) analysis is done daily by health care professionals, such as 
regulators, practicing physicians, and employees of insurance companies, to evaluate 
the safety and efficacy of different medical compounds. Popular indices of therapeutic 
benefit include the treatment effect, generally expressed as either the absolute change 
or the relative change in the rate of events, and the number of patients who need to be 
treated to attain one positive outcome or to prevent one adverse outcome. The harmful 
effects of treatment can be presented in a similar way. Although simple aggregate 
measures such as the numbers needed to treat and the numbers needed to harm seem 
easy to interpret, drug BR analysis generally includes various benefit and risk criteria 
and consequently must include value judgments (1-3). In such a setting, the use of 
Multi-Criteria Decision Analysis (MCDA) may be more appropriate as it provides a 
framework for analyzing complex decision problems involving value trade-offs. 
The use of MCDA in the context of drug BR analysis was first proposed by Mussen et 
al. (4). Their work included a general framework for constructing a multi-criteria 
decision model for BR assessment of new drugs by regulatory authorities. Although 
being an important seminal work in the field, they score alternative drugs on the 
different benefit and risk criteria solely based on point estimates, thereby ignoring the 
sampling variation that is inherent in criteria measurements that are based on clinical 
trials and/or observational studies. In addition, the approach suggested by Mussen et 
al. (4) requires Decision Makers (DMs) to provide exact weights for describing the 
relative importance of the different criteria. In many real-life situations, however, 
DMs are not able to (or do not want to) restrict themselves to one particular set of   4 
weights. Felli et al. (5) provided a similar application of MCDA in drug BR analysis. 
However, instead of using continuous measurements, the authors proposed to use 
categorical value scales for all BR attributes included in the model. Although it makes 
the model easier to apply in different contexts, there is a substantial risk of losing 
information by mapping measurements from a continuous scale to ordinal categories. 
To overcome the limitations of the two previous approaches, we propose to use 
Stochastic Multicriteria Acceptability Analysis (SMAA) (6-8) as a new approach to 
drug BR analysis. Our choice of the SMAA methodology is supported by its proven 
applicability in risk assessment (9, 10) and published real-life analyses alike (11-17). 
To demonstrate its applicability in drug BR analysis, we will apply the SMAA-2 
method (7) in the setting of a recently published meta-analysis considering the 
potential benefits and risks of several commonly prescribed second-generation 
antidepressants (18).  
2  Methods 
2.1  Stochastic Multicriteria Acceptability Analysis 
SMAA-2 considers a discrete multi-criteria decision problem consisting of a set of m 
alternatives (such as different types of drugs) that are evaluated in terms of n criteria 
(such as several efficacy and safety criteria). The vector of criteria measurements 
corresponding to alternative i is denoted by  ) , , ( 1
i
n
i i x x K = x , where 
i
k x  represents the 
performance of alternative i on criterion k . It is assumed that the DM’s preference 
structure can be represented by a real-valued utility or value function  ) (x u . The value 
function serves to rank the m  alternatives by mapping their performance on the 
different criteria to a scalar index of preferability or value. It has the property that   5 
alternative i is preferred over alternative  j  if and only if  ) ( ) (
j i u u x x > . Although 
SMAA-2 can be applied with any type of value function, it is generally assumed that 
all criteria are mutually preferentially independent (19), which implies that the value 
function is additive, and the partial value functions  ) ( k k x u  are used to normalize the 
criteria measurements by mapping them on a zero-to-one scale. The partial value 
functions can be obtained from the actual criteria measurements 
m
k k x x , ,
1 K  through 
linear scaling, so that the worst value is 0 and the best value is 1. The additive value 
function is of form: 
) ( ) ( ) ( 1 1 1 n n n x u w x u w u ⋅ + + ⋅ = K x , 
where the weights  k w  (normalized, so that they sum to one) rescale the values of the 
partial value functions in such a way that the full swing (i.e. increase from the worst 
to the best value) in the scaled function indicates the importance of the criterion (20). 
For example,  j i w w >  implies that if the DM had to choose between improving either 
criterion i or criterion  j  from the worst to the best value, he or she would increase 
the performance on criterion i. 
The SMAA methodology has been developed for situations where neither criteria 
measurements nor weights are precisely known. So, instead of using deterministic 
values, probability distributions are specified for all criteria measurements 
i
k x  that are 
included in the model (in our setting, appropriate shapes for these distributions are 
derived from clinical trials and/or observational studies). Similarly, the DMs’ 
unknown preferences are represented by a uniform weight distribution in the feasible 
weight space  } 1 , 0 | {
1





n w w R W w .   6 
Instead of using the value function to rank the alternatives for an elicited weight 
vector  ) , , ( 1 n w w K = w , which is the traditional approach in MCDA, SMAA computes 
for each alternative the weights a “typical” DM supporting this alternative would 
have. These so-called central weight vectors can be presented to the DM to help him 
or her understand what kind of weights favor a certain alternative, without providing 
any preference information. Mathematically speaking, the central weight vector of an 
alternative is defined as the expected center of gravity of all possible weight vectors 
that rank the alternative at the first place (c.f. (7)). It is expressed as a 
multidimensional integral over the criteria and weight distributions and can therefore 
be numerically computed by using Monte Carlo simulation (21). In each Monte Carlo 
iteration, values for the model parameters (i.e. criteria measurements and weights) are 
drawn from their corresponding distributions, and a ranking of the alternatives is 
obtained by plugging these values into the value function. For the alternative that is 
ranked at the first place, the current sampled weight vector is stored in a table, and the 
simulation proceeds with the next iteration. After all Monte Carlo iterations have been 
completed, an alternative’s central weight vector is computed by averaging over all 
stored weight vectors that are associated with this alternative. 
In addition to the central weight vectors, SMAA-2 defines two other types of 
descriptive measures: rank acceptability indices and confidence factors. The rank 
acceptability index, denoted by  ) , ( r i b , describes the share of all possible values of 
the weight vector w  and imprecise criteria measurements 
m x x , ,
1 K  for which 
alternative i is ranked at place r. Its value can be interpreted as the probability that 
alternative i is ranked at place r, where 0 indicates that the alternative will never 
obtain rank r and 1 indicates that alternative i will always obtain rank r.   7 
The confidence factor of an alternative is the probability for this alternative to obtain 
the first rank when its central weight vector is used to scale the partial value 
functions. If there is no uncertainty in the criteria measurements, the confidence factor 
of each alternative will be equal to 1. In our setting, however, the criteria 
measurements are considered to be stochastic variables, so we are likely to obtain 
confidence factors of less than 1 for at least some of the alternatives included in the 
model. Just like the central weight vectors, the rank acceptability indices and the 
confidence factors can numerically be computed by using Monte Carlo simulation. In 
practice, the computation of the descriptive indices can be made more efficient than 
described here. For more details on the implementation of SMAA-2 based on Monte 
Carlo simulation, the reader is referred to (21). 
So far, we considered the case when the SMAA analysis is conducted without any 
preference information. In practice, however, it may be possible to elicit some 
preference information from the DMs, such as a partial or complete ranking of the 
criteria. This information can easily be incorporated into the model by restricting the 
feasible weight space accordingly (c.f. (21)). If there is no preference information, the 
decision making is aided mainly through central weight vectors and confidence 
factors. When preference information is incorporated into the model, the rank 
acceptability indices can be used for finding the “best” alternative and for quantifying 
the risks related to uncertainty of outcomes.  
2.2  Model for the therapeutic group of antidepressants 
To demonstrate the application of SMAA in drug BR analysis, we constructed a 
model for the therapeutic group of antidepressants using efficacy and safety data from 
a published meta-analysis (18). We would like to stress that our model is illustrative   8 
in nature, meaning that the results should not be interpreted as a full BR assessment of 
the different drugs included in the model. 
2.2.1  Criteria 
In the meta-analysis, the efficacy and safety of ten commonly prescribed second-
generation antidepressants were compared (18). From this study, we selected the four 
antidepressants for which sufficient quantitative data was available: Fluoxetine, 
Paroxetine, Sertraline, and Venlafaxine. The criteria used to evaluate these four drugs 
are summarized in Table 1. We included one benefit criterion (treatment response) 
and five risk criteria, each corresponding to a different adverse event (diarrhea, 
dizziness, headache, insomnia, and nausea). There is a certain overlap between 
efficacy and insomnia, because improved efficacy can lead to less insomnia. For sake 
of simplicity, we disregarded this possible source of double-counting and assumed the 
criteria to be independent. 
Treatment response, defined as an improvement of at least 50% on either the 
Hamilton Rating Scale for Depression (HAM-D) or the Montgomery-Asberg 
Depression Rating Scale from baseline to the end of the follow-up period, was used as 
a measure of efficacy in all clinical trials that were included in the meta-analysis. The 
authors conducted three separate analyses (effects were combined by using a random 
effects model) to estimate the relative efficacy (i.e. the proportion of respondents in 
one treatment group divided by the proportion of respondents in another treatment 
group) of (i) Paroxetine over Fluoxetine, (ii) Sertaline over Fluoxetine, and (iii) 
Venlafaxine over Fluoxetine. The frequency at which a specific adverse event 
occurred was reported in the meta-analysis as the mean incidence across all 
comparative trials and observational studies that included this event.   9 
SMAA allows the criteria measurements to be modeled with arbitrary distributions. In 
our setting, the distributions follow directly from the results of the meta-analysis. In 
particular, it follows that the pooled incidences of the adverse events as well as the 
log of the pooled efficacy ratios can be considered as independently and normally 
distributed random variables (22). The means 
i
k µ of these distributions are taken to be 
equal to the (log of the) pooled effect-size estimates, and the standard deviations 
i
k σ  
are derived from the corresponding 95% confidence intervals as reported in the meta-
analysis. For example, the pooled incidence of diarrhea for Fluoxetine was found to 
be equal to 11.7 with a 95% confidence interval of [6.8, 16.6] (18). The upper (lower) 
bound of this confidence interval was computed by adding (subtracting) 
Fluoxetine
Diarrhea σ ⋅ 96 . 1  to (from) the effect-size estimate of 11.7, so the estimated standard 
deviation of the pooled incidence of diarrhea for Fluoxetine will be equal to 
  5 . 2
96 . 1 2






Diarrhea σ . 
2.2.2  Preference information 
We performed three analyses: one with missing preference information, and two with 
a criteria ranking elicited from an expert in the field of antidepressants. For the latter, 
we explained the SMAA model and multi-attribute utility theory to the expert and 
asked her to consider a scenario of mild depression and a scenario of severe 
depression. 
For both of these scenarios, we started by asking the expert to identify the criterion 
that she would most like to increase from the worst to the best value, given the range 
of the scales as depicted in Table 1. Then we asked for the second one, etc. This   10 
process is similar to swing weighting in multi-attribute utility theory (23). However, 
since no exact “weights” are required, it resembles more the environment of medical 
decision making. 
Let us denote by f the strict preference relation. The elicitation process resulted in 
the following ranking for mild depression: Diarrhea f Nausea f Dizziness f 
Insomnia f Headache f Efficacy. For severe depression the ranking was similar 
with the exception of efficacy being the most preferred criterion (i.e. Efficacy 
fDiarrhea f Nausea f Dizziness f Insomnia f Headache). 
2.3  Software 
All analyses were conducted by using the JSMAA v0.2 software, an open source 
implementation of the SMAA methods in Java that is freely available from: 
http://www.smaa.fi. 
3  Results 
We completed the models with the criteria measurements listed in Table 2. The three 
analyses were executed with 10,000 Monte Carlo iterations, thereby giving the results 
sufficient accuracy (95% confidence error margins of ± 0.01) (21).  
3.1  No preference information 
The rank acceptability indices resulting from the analysis without preference 
information are listed in Table 3 and visualized as a column chart in Figure 1. These 
indices show that all drugs have reasonable BR profiles and should be considered for 
further analysis. In a situation like this, the decision can be aided through the central 
weight vectors (see Table 4). By looking at the central weights, we can see clear   11 
trade-offs among the four drugs. For example, if the DM displays an a priori 
preference of Paroxetine, then based on the BR profiles expressed through the central 
weights, apparently nausea has the highest relative importance. If the DM accepts our 
model and is rational, he or she should favor lowering first nausea from the worst 
scale value (34%) to the best one (11.1%). 
By contrasting a DM’s preferences for scale swings (Table 1) with the central weights 
presented in Table 4, the DM can quickly decide which drug is preferable in the 
current situation. For example, if a DM considers the scale swing of efficacy (0.25) 
more important than the scale swing of dizziness (20.0, see Table 1), then he or she 
should prefer the BR profile of the three other drugs over Fluoxetine, because it is the 
only drug for which the central weight of efficacy is considerably lower than the 
central weight of dizziness. In addition, the confidence factors (Table 4) quantify the 
risk associated with the decision. For example, if a DM finds Fluoxetine’s central 
weight vector to correspond with his or her preferences, the confidence factor (0.48) 
shows that the clinical data is too uncertain for making a truly informed decision. 
3.2  Mild and severe depression 
Rank acceptability indices for the scenario of mild (severe) depression are presented 
in Table 5 (Table 6) and illustrated in Figure 2 (Figure 3). Both the mild and severe 
depression scenarios lead to a relatively high first rank acceptability for Paroxetine. It 
had also a good rank profile in the analysis without preference information, and thus 
could be considered to have the “best” (i.e. reasonably high rank acceptabilities for 
the best ranks and low acceptabilities for the worst ranks) overall BR profile if no 
additional information is available. The rank acceptabilities of the other alternatives 
are more sensitive to the preferences. For example, the rank profile of Fluoxetine   12 
depends completely on preferences. It achieves a significantly higher first rank 
acceptability (0.30) for the mild depression scenario than for the severe depression 
scenario (0.01). For Venlafaxine, the case is opposite: its first rank acceptability is a 
lot higher for severe depression (0.40) than for mild depression (0.21). 
4  Discussion 
Drug BR analysis has multiple uses, ranging from regulatory decision making to 
supporting decisions of a practicing physician. The MCDA-based approach suggested 
in this paper can be adapted for all contexts. As an example, we constructed a multi-
attribute model for the therapeutic group of antidepressants by using data from a 
published meta-analysis. Despite the fact that the differences among the four 
antidepressants were mostly insignificant from a frequentist perspective, our results 
show that there are clear trade-offs among these drugs when the uncertainty 
surrounding the criteria measurements is taken into account. This could be seen from 
the central weight vectors of the analysis without preference information, and also 
from the rank acceptability indices of the analyses of the mild and severe depression 
scenarios that differed only in preference of the efficacy criterion. 
Instead of having a different model for each therapeutic group, one could also 
consider constructing a more generic model by using the dimensions of an existing 
utility instrument, such as the EQ-5D or the Health Utilities Index. Although such 
instruments are suitable for calculating QALYs in the context of cost-effectiveness 
analysis, there is an important drawback when using them for drug BR analysis: their 
dimensions are defined in terms of generic health attributes—such as physical 
functioning, social functioning, and vitality—and may therefore not be very sensitive 
and responsive to the disease of interest. So, although our results have shown that   13 
there are clear trade-offs among the four antidepressants, the relative differences in 
safety and efficacy may not be large enough to significantly change a patient’s health 
status when this is measured in terms of generic health attributes. 
Compared to the MCDA-based approaches proposed by Mussen et al. (4) and Felli et 
al. (5), the use of SMAA has two main advantages. The first advantage of the SMAA 
methodology is the possibility to include the sampling variation that is inherent in 
criteria measurements that are based on clinical trials. Mussen et al. (4) and Felli et al. 
(5), in contrast, do not explicitly include parameter uncertainty into their models: they 
solely rely on point estimates when assessing the performance of each of the 
alternatives against the different BR criteria. The capability of our model to propagate 
uncertainty to the results (in terms of rank acceptability indices and confidence 
factors) allows us to quantify the risks that are associated with any decision that is 
based on the results of the BR analysis. 
The second advantage of the SMAA methodology over the two existing approaches is 
the possibility to characterize typical trade-offs supporting a drug BR profile without 
knowing or eliciting the preferences beforehand. The possibility to use our model 
without any preferences as well as with scenario-based ordinal preferences lowers the 
effort required to apply the model in different situations, and also increases the 
transparency of the decision making process. 
The scenario-based rank acceptabilities can be used in operational support of 
decisions depending on drug BR analysis. If a drug has low (<0.20) rank 
acceptabilities for the first ranks, additional risk management practices should be used 
if that drug is chosen. For example, in our scenario of severe depression, Fluoxetine 
obtained a cumulative acceptability of only 0.06 for the first two ranks. If the BR   14 
analysis leads to prescription decision of Fluoxetine due to external constraints (local 
reimbursement policy, patient profile including allergies, etc), the future patient 
consultancy should be sensitive to change of medication as other drugs with "better" 
BR profiles are available. 
To conclude, we presented a new MCDA-based approach to drug BR analysis with an 
example application to the therapeutic group of second-generation antidepressants. In 
contrast to previous models, our model is based on the SMAA methodology, which 
allows us to take into account the sampling variation that is inherent in criteria 
measurements that are based on clinical trials and/or observational studies. In 
addition, by making the trade-offs among the four analyzed drugs explicit, we 
separated clinical data from subjective judgments, thereby increasing the transparency 
of the decision making process. The constructed model is specific to the therapeutic 
group of antidepressants, and future research should analyze the applicability of the 
SMAA methodology to other therapeutic groups. 
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Table 1: Criteria characteristics. 





Relative value compared with 
Fluoxetine 
↑  [0.98, 1.23] 
Diarrhea 
ADE’s 
Absolute %  ↓  [1, 20.6] 
Dizziness 
ADE’s 
Absolute %  ↓  [4.4, 24.4] 
Headache 
ADE’s 
Absolute %  ↓  [8, 31.3] 
Insomnia 
ADE’s 
Absolute %  ↓  [3.4, 21.3] 
Nausea ADE’s  Absolute %  ↓  [11.1, 34]   18 
 
Table 2: Criteria measurements. The values are given as mean ± standard deviation. The 
measurement units are as presented in Table 1. 
Drug  Ln(Efficacy)  Diarrhea  Dizziness  Headache  Insomnia  Nausea 
Fluoxetine  0 ± 0  11.7 ± 2.5  7.2 ± 1.45  16.6 ± 3.27  13.7 ± 1.89  18.6 ± 1.79 
Paroxetine  0.086 ± 0.056  9.2 ± 1.86  10.6 ± 1.58  21.2 ± 5.15  14.3 ± 2.93  18.3 ± 3.7 
Sertraline  0.095 ± 0.044  15.4 ± 2.65  7.5 ± 1.48  20.2 ± 3.78  15 ± 3.21  19.5 ± 2.6 
Venlafaxine  0.113 ± 0.048  5.5 ± 2.32  15.7 ± 4.44  12.8 ± 2.45  11.2 ± 3.98  31 ± 1.68 
 
Table 3: Rank acceptability indices from the analysis without preference information. In 
columns of Rank 2 and 3 also the cumulative indices from Rank 1 are presented. 





























0.29   19 
Table 4: Central weights and corresponding confidence factors from the analysis without 
preference information. 
Central weight vector 
Drug 
Conf. 
factor  Efficacy  Diarrhea  Dizziness  Headache  Insomnia  Nausea 
Fluoxetine  0.48  0.08  0.14  0.23  0.18  0.16  0.22 
Paroxetine  0.45  0.18  0.17  0.15  0.13  0.15  0.22 
Sertraline  0.34  0.21  0.10  0.22  0.13  0.15  0.20 
Venlafaxine  0.74  0.18  0.21  0.12  0.21  0.19  0.09 
 
Table 5: Rank acceptability indices from the scenario of mild depression. 
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Table 6: Rank acceptability indices from the scenario of severe depression. 






























































































Figure 3: Rank acceptability indices for the scenario of severe depression. 
 
 